$INBX
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Healthcare
Sector
Biotechnology
Industry
Mark Paul Lappe
CEO
156
Employees
$88.67
Current Price
$1.06B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 1 | 6 | $848,976.84 | 10,040 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 3 | 20 | $6,347,357.09 | 62,540 | 22.75:1 |
| Sells | 1 | 5 | $279,010.00 | 2,500 | ||
| 3 months | Buys | 3 | 20 | $6,347,357.09 | 62,540 | 22.75:1 |
| Sells | 1 | 5 | $279,010.00 | 2,500 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Oct 14, 2026 | Lappe Mark Director | Purchase | 100 | $85.76 | $8,576.00 | View Details |
| Oct 14, 2026 | Lappe Mark Director | Purchase | 100 | $85.76 | $8,576.00 | View Details |
| Oct 14, 2026 | Lappe Mark Director | Purchase | 2,470 | $85.00 | $209,948.02 | View Details |
| Oct 14, 2026 | Lappe Mark Director | Purchase | 2,451 | $85.00 | $208,333.04 | View Details |
| Oct 14, 2026 | Lappe Mark Director | Purchase | 2,449 | $84.07 | $205,889.14 | View Details |
| Oct 14, 2026 | Lappe Mark Director | Purchase | 2,470 | $84.07 | $207,654.63 | View Details |
| Sep 25, 2026 | Lappe Mark Director | Purchase | 3,324 | $98.87 | $328,630.25 | View Details |
| Sep 25, 2026 | Lappe Mark Director | Purchase | 2,176 | $99.60 | $216,726.99 | View Details |
| Sep 28, 2026 | Lappe Mark Director | Purchase | 1,500 | $98.88 | $148,320.45 | View Details |
| Sep 28, 2026 | Lappe Mark Director | Purchase | 3,000 | $101.70 | $305,106.00 | View Details |
| Sep 23, 2026 | Kayyem Jon Faiz Director | Purchase | 5,000 | $100.00 | $500,000.00 | View Details |
| Sep 16, 2026 | Kayyem Jon Faiz Director | Purchase | 5,000 | $100.00 | $500,000.00 | View Details |
| Sep 11, 2026 | MANHARD KIMBERLY Director | Sale | 500 | $111.78 | $55,887.50 | View Details |
| Sep 14, 2026 | MANHARD KIMBERLY Director | Sale | 500 | $110.26 | $55,130.00 | View Details |
| Sep 15, 2026 | MANHARD KIMBERLY Director | Sale | 500 | $105.05 | $52,525.00 | View Details |
| Sep 8, 2026 | MANHARD KIMBERLY Director | Sale | 500 | $115.14 | $57,570.00 | View Details |
| Sep 9, 2026 | MANHARD KIMBERLY Director | Sale | 500 | $115.80 | $57,897.50 | View Details |
| Sep 8, 2026 | Kayyem Jon Faiz Director | Purchase | 5,000 | $113.52 | $567,580.00 | View Details |
| Sep 8, 2026 | FORSYTH DOUGLAS Director | Purchase | 2,500 | $114.65 | $286,617.25 | View Details |
| Sep 8, 2026 | Lappe Mark Director | Purchase | 500 | $108.23 | $54,117.50 | View Details |
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$2.45
ActualN/A
Revenue
Estimated$1.90M
ActualN/A
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Related Activity
Cross-company insider connections and cluster buy signals
Cluster Buy Signals
$INBX appeared in 2 cluster buy signals: